`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`Celltrion, Inc.
`Petitioner,
`
`v.
`
`Genentech, Inc.
`Patent Owner
`
`Patent No. 6,407,213
`
`
`
`
`
`
`
`Inter Partes Review No. IPR2017-01373
`
`
`
`
`
`
`
`
`
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`EXHIBIT
`NO.
`
`1001
`
`DESCRIPTION
`
`U.S. Patent No. 6,407,213, Method for making humanized antibodies
`(filed Jul. 17, 1993) (issued June 18, 2002)
`
`1002 Part I File History for U.S. Patent No. 6,407,213 Part I
`
`1002 Part II File History for U.S. Patent No. 6,407,213 Part II
`
`1003
`
`1003A
`
`1003B
`
`1003C
`
`1004
`
`1004A
`
`1004B
`
`1005
`
`1006
`
`1007
`
`1008
`
`Declaration of Dr. Lutz Riechmann, Ph.D. in Support of Petition for
`Inter Partes Review of Patent No. 6,407,213
`
`Curriculum Vitae of Dr. Lutz Riechmann, Ph.D.
`
`Materials Reviewed by Dr. Lutz Riechmann, Ph.D.
`
`Exhibits A-O of Dr. Lutz Riechmann, Ph.D.
`
`Declaration of Dr. Robert Charles Fredrick Leonard, M.D. in Support
`of Petition for Inter Partes Review of Patent No. 6,407,213
`
`Curriculum Vitae of Dr. Robert Charles Fredrick Leonard, M.D.
`
`Materials Reviewed by Dr. Robert Charles Fredrick Leonard, M.D.
`
`Ball E.D., et al. Studies on the ability of monoclonal antibodies to
`selectively mediate complement-dependent cytotoxicity of human
`myelogenous leukemia blast cells. J. Immunol. 128(3):1476–81
`(March 1982)
`
`Ball, E.D., et al. Monoclonal antibodies reactive with small cell
`carcinoma of the lung. J. Nat’l Cancer Inst. 72(3):593–98 (March
`1984)
`
`Magnani, J.L., Ball, E.D., et al. Monoclonal antibodies PMN 6, PMN
`29 and PM-81 bind differently to glycolipids containing a sugar
`sequence occurring in lacto-N-fucopentaose III, Arch. Biochem.
`Biophys. 233(2):501–06 (September 1984)
`
`Memoli, V.A., Jordan, A.G., and Ball, E.D. A novel monoclonal
`antibody, SCCL 175, with specificity for small cell neuroendocrine
`carcinoma of the lung. Cancer Res. 48:7319–22 (December 15, 1988)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`Ball E.D., et al. Monoclonal antibodies to myeloid differentiation
`antigens: in vivo studies of three patients with acute myelogenous
`leukemia. Blood 62(6):1203–10 (December 1983)
`
`Ball E.D., et al. Phase I clinical trial of serotherapy in patients with
`acute myeloid leukemia with an immunoglobulin M monoclonal
`antibody to CD15. Clin Cancer Res 1:965–72 (September 1995)
`
`Bashey A., Ball E.D., et al. CTLA4 Blockade with Ipilimumab to Treat
`Relapse of Malignancy after Allogeneic Hematopoietic Cell
`Transplantation. Blood 113(7):1581–88 (2009)
`
`Armand P., Ball E.D., et al. Disabling Immune Tolerance by
`Programmed Death-1 Blockade with Pidilizumab after Autologous
`Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell
`Lymphoma: Results of an International Phase II Trial. J. Clin. Oncol.
`31(33):4199–4206 (November 20, 2013)
`
`Ball E.D., et al. Initial trial of bispecific antibody-mediated
`immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor
`cells using a bispecific antibody comprised of anti-CD15 (MoAb
`PM81) and anti-CD64/Fc gamma RI (MoAb 32). J. Hematotherapy
`1:85–94 (1992)
`
`Chen J, Zhou J.H., Ball E.D. Monocyte-mediated lysis of acute
`myeloid leukemia cells in the presence of the bispecific antibody 251 x
`22 (anti-CD33 x anti-CD64). Clin. Can. Res. 1:1319–25(November
`1995)
`
`Balaian, L. and Ball, E.D. Direct effect of bispecific anti-CD33 x anti-
`CD64 antibody on proliferation and signaling in myeloid cells.
`Leukemia Res. 25:1115–25 (2001)
`
`Chen J., Ball, E.D., et al. An immunoconjugate of Lys3-bombesin and
`monoclonal antibody 22 can specifically induce FcgammaRI (CD64)-
`dependent monocyte- and neutrophil-mediated lysis of small cell
`carcinoma of the lung cells. Clin. Can. Res. 1:425–34 (April 1995)
`
`Chen J., Ball, E.D., et al. Monocyte- and neutrophil-mediated lysis of
`SCCL by a bispecific molecule comprised of Lys3-BN and mAb22.
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`Peptides 1994. 819–20(1995)
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`Zhou J.H., Ball E.D., et al. Immunotherapy of a human small cell lung
`carcinoma (SCLC) xenograft model by the bispecific molecule (BsMol)
`mAb22xLys3-Bombesin (M22xL-BN). Peptides 1996, 935–36 (1998)
`
`Ball, E.D. and Balaian, L. Cytotoxic activity of gemtuzumab
`ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the
`expression of protein kinase Syk. Leukemia, 20:2093–2101 (2006)
`
`Ball E.D., et al. Update of a phase I/II trial of5-azacytidine prior to
`gemtuzumab ozogamicin (GO) for patients with relapsed acute
`myeloid leukemia with correlative biomarker studies [abstract]. Blood
`(ASH Annual Meeting Abstracts) 116: Abstract 3286 (2010)
`Hudziak et al. p185HER2 Monoclonal Antibody Has Antiproliferative
`Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor
`Necrosis Factor. Mol. Cell Biol. 9(3):1165–72 (March 1989)
`
`Kohler and Milstein, Continuous Cultures of Fused Cells Secreting
`Antibody of Predefined Specificity. Nature 256(5517):495–97 (August
`7, 1975)
`
`Prabakaran, S. The Quest for a Magic Bullet Science, 349(6246):389
`(July 24, 2015)
`
`Marks, L. The story of Cesar Milstein and Monoclonal Antibodies: A
`Healthcare Revolution in the Making at
`http://www.whatisbiotechnology.org/exhibitions/milstein (last accessed
`September 08, 2015)
`
`Cosimi et al., Treatment of Acute Renal Allograft Rejection with OKT3
`Monoclonal Antibody. Transplantation 32:535–39 (1981)
`
`Ortho Multicenter Transplant Study Group, A Randomized Clinical
`Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadveric
`Renal Transplants. N. Engl. J. Med. 313(6):337–42 (August 8, 1985)
`
`Jaffers et al. Monoclonal Antibody Therapy. Anti-idiotypic and Non-
`anti-idiotypic antibodies to OKT3 Arising Despite Intense
`
`
`
`EXHIBIT
`NO.
`
`1028
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`DESCRIPTION
`Immunosuppression. Transplantation 41(5):572–78 (1986)
`
`Sears et al. Phase-I clinical trial of monoclonal antibody in treatment
`of gastrointestinal tumours. The Lancet 762–65 (April 3, 1982)
`
`Sikora Monoclonal antibodies in oncology. J. Clin. Pathol. 35:369–75
`(1982)
`
`“Protein Data Bank - Chronology” at
`https://www.nsf.gov/news_summ_jsp?cntn_id=100689 (accessed
`August 29, 2016)
`
`Morrison et al., Chimeric Human Antibody Molecules: Mouse Antigen-
`Binding Domains with Human Constant Region Domains. Pro. Nat’l
`Acad. Sci. 81:6851–55 (November 1984).
`
`Liu et al., Chimeric Mouse-human IgG1 Antibody that can Mediate
`Lysis of Cancer cells. Pro. Nat’l Acad. Sci. 84:3439–43 (May 1987).
`
`Jones et al. Replacing the Complementarity-Determining Regions in a
`Human Antibody with those from a Mouse. Nature 321:522–25 (1986)
`
`Queen et al. A Humanized Antibody that Binds to the Interleukin 2
`Receptor. Pro. Nat’l Acad. Sci. 86:10029–33 (1989)
`
`Kirkman et al., Early Experience with anti-Tac in Clinical Renal
`Transplantation. Transplant. Proc. 21:1766–68 (1989)
`Waldmann et al. The Interleukin-2 Receptor: A Target for Monoclonal
`Antibody Treatment of Human T-Cell Lymphotrophic Virus I-Induced
`Adult T-Cell Leukemias. Blood 72:1705–16 (1988)
`
`Hakimi et al. Reduced Immunogenicity and Improved
`Pharmacokinetics of Humanized anti-Tac in Cynomolgus Monkeys. J.
`Immunol. 147:1352–59 (August 15, 1991)
`
`Vincenti et al., Interleukin 2-Receptor Blockade with Daclizumab to
`Prevent Acute Rejection in Renal Transplantation. N. Engl. J. Med.
`338(3):161–65 (January 15, 1998)
`
`
`
`EXHIBIT
`NO.
`
`1039
`
`1040
`
`1041
`
`1042
`
`1043
`
`1044
`
`1045
`
`1046
`
`1047
`
`1048
`
`DESCRIPTION
`SEER Stat Fact Sheets: Breast Cancer at
`http://seer.cancer.gov/statfacts/html/breast.html (last accessed
`September 08, 2015)
`
`Harris, J.R., et al. Medical Progress: Breast Cancer. N. Engl. J. Med.
`327(5):319–28 (1992)
`
`King C.R., Kraus M.H., and Aaronson, S.A. Amplification of a Novel
`v- erbB-Related Gene in a Human Mammary Carcinoma. Science
`229:974–76 (1985)
`
`Semba K., et al. A v-erbB-related protooncogene, c-erbB-2, is distinct
`from the c-erbB-1/epidermal growth factor-receptor gene and is
`amplified in a human salivary gland adenocarcinoma. Pro. Nat’l
`Acad. Sci. 82:6497–6501 (1985)
`
`Coussens L., et al. Tyrosine kinase receptor with extensive homology
`to EGF receptor shares chromosomal location with neu oncogene.
`Science 230:1132–39 (December 6, 1985)
`
`Fukushige S., et al. Localization of a Novel v-erbB-Related Gene, c-
`erbB-2, on Human Chromosome 17 and its Amplification in a Gastric
`Cancer Cell Line. Mol. Cell. Biol. 6:955–58 (1986)
`
`Slamon, D.J. et al. Human Breast Cancer Correlation of Relapse and
`Survival with Amplification of the HER-2/neu Oncogene. Science
`235:177–82 (1987)
`
`Kraus, M.H., et al. Overexpression of the EGF receptor-related proto-
`oncogene erbB-2 in human mammary tumor cell lines by different
`molecular mechanisms. The EMBO Journal 6(3):605–10 (1987)
`
`Hudziak, R. M., et al. Increased expression of the putative growth
`factor receptor p185HER2 causes transformation and tumorigenesis
`of NIH 3T3 cells. Pro. Nat’l Acad. Sci. 84:7159–63 (1987)
`
`Shepard, H. M. et al. Monoclonal Antibody Therapy of Human
`Cancer: Taking the HER2 Protooncogene to the clinic. Journal of
`Clinical Immunology, 11(3):117–27 (1991).
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1049
`
`1050
`
`1051
`
`1052
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`Chothia, C. et al. Conformations of immunoglobulin hypervariable
`regions. Nature 342(21):877–83 (December 1989).
`
`Queen, Cary L.: International Publication No. WO 1990/07861
`(published July 26, 1990)
`
`Tramontano, A. et al. Framework Residue 71 is a Major Determinant
`of the Position and Conformation of the Second Hypervariable Region
`in the VH Domains of Immunoglobulins, J. Mol. Biol. 215:175–82
`(1990)
`Kabat, et al. Sequences of Proteins of Immunological Interest 4th Ed.,
`Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of
`Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for
`Antigen, T-Cell Surface Antigens (National Institutes of Health,
`Bethesda, Md.) (1987)
`
`Wu and Kabat, An analysis of the sequences of the variable regions of
`Bence Jones proteins and myeloma light chains and their implications
`for antibody complementarity. J. Exp. Med. 132:211–50 (1970)
`
`Kieber-Emmons et al. Perspectives on Antigenicity and Idiotypy.
`Intern. Rev. Immunol. 2:339–56 (1987)
`Kabat, et al. Sequences of Proteins of Immunological Interest 5th Ed.,
`Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of
`Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for
`Antigen, T-Cell Surface Antigens (National Institutes of Health,
`Bethesda, Md.) (1991)
`
`Milstein, et al. The Wellcome Foundation Lecture 1980, Monoclonal
`Antibodies from Hybrid Myelomas. Proc. Royal Soc. London 211:393–
`412 (March 27, 1981)
`
`Johnson and Wu The Kabat database and a bioinformatics example,
`Methods in Molecular Biology 248:11–25 (December 2003)
`
`Davies & Metzger, Structural Basics of Antibody Function, Annu.
`Rev. Immunol. 1:87–117 (1983)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1059
`
`1060
`
`1061
`
`1062
`
`1063
`
`1064
`
`1065
`
`1066
`
`1067
`
`1068
`
`1069
`
`1070
`
`Amit et al. Three-Dimensional Structure of an Antigen-Antibody
`Complex at 2.8 A Resolution Science 233:747–53 (1986)
`
`Lascombe et al. Three-dimensional Structure of Fab R19.9, a
`Monoclonal Murine Antibody Specific for the p-azobenzenearsonate
`group. Pro. Nat’l Acad. Sci. 86:607–11 (January 1989)
`
`Novotny et al. Molecular Anatomy of the Antibody Binding Site. J.
`Biol. Chem. 258(23):14433–37 (December 10, 1983)
`
`Chothia and Lesk, Canonical structures for the hypervariable regions
`of immunoglobulins. J. Mol. Biol. 196:901–17 (1987)
`
`Chothia et al. Domain Association in Immunoglobulin Molecules: The
`Packing of Variable Domains. J. Mol. Biol. 186:651–63 (1985)
`
`Van Kroonenburgh & Pauwels Human Immunological Response to
`Mouse Monoclonal Antibody Treatment or Diagnosis of Malignant
`Diseases. Nucl. Med. Commun. 9:919–30 (1988)
`
`Tjandra et al. Development of human anti-murine antibody (HAMA)
`response in patients. Immunol. Cell. Biol. 68:367–76 (1990)
`
`Lind, et al. Development of human antimouse antibodies (HAMA) after
`single and repeated diagnostic application of intact murine
`monoclonal antibodies. Antibod. Immunoconj. Radiopharm. 4(4):811–
`18 (1991)
`
`Mountain and Adair, Engineering Antibodies for Therapy. Biotech.
`Genet. Eng. Rev. 10:1–142 (1992)
`
`Verhoeyen, Milstein & Winter et al. Reshaping Human Antibodies:
`Grafting an Antilysozyme Activity. Science 239:1534–36 (March 25,
`1988)
`
`Riechmann, et al. Reshaping human antibodies for therapy. Nature
`332:323–27 (March 24, 1988)
`
`Tempest, et al. Reshaping a human monoclonal antibody to inhibit
`human respiratory syncytial virus infection in vivo. BioTechnology
`
`
`
`EXHIBIT
`NO.
`
`9:266–71 (March 1991)
`
`DESCRIPTION
`
`1071
`
`1072
`
`1073
`
`1074
`
`1075
`
`1076
`
`1077
`
`1078
`
`1079
`
`1080
`
`Kurrle, et al. Improved monoclonal antibodies against the human
`alphabeta T-Cell receptor, their production and use. EP0403156.
`(1990)
`
`Shearman, et al. Construction, expression and characterization of
`humanized antibodies directed against the human a/b T cell receptor.
`J. Immunol. 147(12):4366–73, (December 15, 1991)
`
`Winter, Gregory Paul et al. EP Publication Number 0239400,
`Recombinant antibodies and methods for their productions. Published
`September 30, 1987.
`
`Accelrys Inc. (http://accelrys.com/micro/insight/insight.html) (Last
`accessed October 16, 2015)
`
`Dayringer et al., Interactive program for visualization and modelling
`of proteins, nucleic acids and small molecules. J. Mol. Graphics
`4(2):82–87 (1986)
`
`Loew, G. et al. Engergy-Conformational Studies of B-Endorphis:
`Identification of Plausible Folded Conformers. Int. J. Quant. Chem.
`Quant. Biol. 15:55–66 (1988)
`
`Bruccoleri et al. Structure of antibody hpervariable loops reproduced
`by a conformational search algorithm. Nature 335(6):564–68 (1988)
`
`Chothia et al. The Predicted Structure of Immunoglobulin D1.3 and its
`Comparison with the Crystal Structure. Science New Series,
`233(4765):755–58 (August 15, 1986)
`
`Kabat et al., Sequences of Proteins of Immunological Interest
`Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of
`Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for
`Antigen, T-Cell Surface Antigens (National Institutes of Health,
`Bethesda, Md.) (1983).
`
`Bernstein et al. The Protein Data Bank: A Computer-based Archival
`File for Macromolecular Structures. J. Mol. Biol. 112:535–42 (1977)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1081
`
`1082
`
`1083
`
`1084
`
`1085
`
`1086
`
`1087
`
`1088
`
`1089
`
`1090
`
`1091
`
`Sheriff et al. Three-Dimensional Structure of an Antibody-Antigen
`Complex, Proc. Nat’l Acad. Sci. U.S.A. 84:8075 (1987)
`
`Marquart et al. The three-dimensional structure of antibodies. Immun.
`Today 3(6):160–66 (1982)
`
`Saul et al. Preliminary Refinement and Structural Analysis of the FAB
`Fragment from Human Immunoglobulin NEW at 2.0 Angstroms
`Resolution. J. Biol. Chem. 253:585 (1978)
`
`Navia et al. Crystal structure of galactan-binding mouse
`immunoglobulin J539 FAB at 4.5 Angstroms resolution. Proc. Natl.
`Acad. Sci. 76(8):4071–74 (August 1979)
`
`Satow et al. Phosphocholine Binding Immunogloubulin Fab McPC306
`An X-ray Diffraction Study at 2*A. J. Mol. Biol. 190:593–604 (1986)
`
`Herron et al. Three-Dimensional Structure of a Flourescein-Fab
`Complex Crystallized in 2-Methyl-2, 4-pentanediol. Proteins 5:271–80
`(1989)
`
`Padlan et al. Structure of an antibody-antigen complex: crystal
`structure of the HYHEL-10 FAB-lysozyme complEx. Proc. Nat’l Acad.
`Sci. 86:5938–942 (August 1989)
`
`Kumar et al. Regulation of phosphorylation of the c-erbB-2/HER2
`gene product by monoclonal antibody and serum growth factor(s) in
`human mammary carcinoma cells. Mol. Cell. Biol. 11(2):979–86
`(February 1991)
`
`Soomro et al. C-erbB-2 expression in different histological types of
`invasive breast carcinoma. J. Clin. Pathol. 44:211–14 (1991)
`
`Keith Wilson & Kenneth H. Goulding, A Biologist’s Guide to
`Principles and Techniques of Practical Biochemistry, §Protein
`sequencing, 170–73 (3rd ed., 1986)
`
`Edelman et al. The Covalent Structure of an Entire γG
`Immunoglobulin Molecule. Proc. Nat’l Acad. Sci 63:78–85 (1969)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1092
`
`1093
`
`1094
`
`1095
`
`1096
`
`1097
`
`1098
`
`1099
`
`1100
`
`1101
`
`1102
`
`Capra, J. Donald and Kehoe, K. Michael Variable Region Sequences
`of Five Human Immunoglobulin Heavy Chains of the VHIII Subgroup:
`Definitive Identification of Four Heavy Chain Hypervariable Regions.
`Proc. Nat’l Acad. Sci. 71:845–8 (1974)
`
`Morin, Michael J. From Oncogene to Drug: Development of Small
`Molecule Tyrosine Kinase Inhibitors as Anti-tumor and Anti-
`angiogenic agents. Oncogene 19:6574–83 (2000)
`
`File History for U.S. Patent Application No. 07/715,272
`Immunoglobulin Variants (filed June 14, 1991).
`
`File History for Patent Interference No. 105,744 (Senior party
`Application No. 11/284,261, Inventors John Robert Adair et al. Junior
`Party, U.S. Patent 6,407,213, Inventors Paul J. Carter and Leonard G.
`Presta)
`
`US Patent No. 5,677,171 Monoclonal antibodies directed to the HER2
`receptor, (filed August 5, 1994) (Issued October 14, 1997).
`
`Sambrook et al., Molecular Cloning (2d ed., Cold Spring Harbor
`Laboratory Press) (1989)
`
`Daugherty et al., Polymerase chain reaction facilitates the cloning,
`CDR-grafting and rapid expression of a murine monoclonal antibody
`directed against the CD18 component of leukocyte integrins. Nucl.
`Acids Res. 19(9):2471–76 (May 1991).
`
`Padlan and Kabat, Modeling of Antibody Combining Sites Meth.
`Enzymol. 203:3 (1991).
`
`Colman et al., Three-dimensional structure of a complex of antibody
`with influenza virus neuraminidase, Nature 326:358 (1987)
`
`Tulip et al., Crystal structures of neuraminidase-antibody complexes,
`Cold Spring Harbor Symp. Quant. Biol. 4:257 (1989)
`
`Bender et al., Immunogenicity, efficacy and adverse events of
`adalimumab in RA patients. Rheumatol. Int. 27:269–74 (2007)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1103
`
`1104
`
`1105
`
`1106
`
`1107
`
`1108
`
`1109
`
`1110
`
`1111
`
`1112
`
`1113
`
`Brient, Bruce W. and Nisonoff, Alfred Quantitative investigations of
`idiotypic antibodies. IV. Inhibition by specific haptens of the reaction
`of anti-hapten antibody with its anti-idiotypic antibody, J Exp Med.
`132:951–62 (1970)
`
`Koprowski et al., Human anti-idiotype antibodies in cancer patients:
`Is the modulation of the immune response beneficial for the patient?
`Proc. Nat’l. Acad. Sci. U.S.A. 81:216 (1984)
`
`Chanh et al., Monoclonal anti-idiotypic antibody mimics the CD4
`receptor and binds human immunodeficiency virus, Proc. Nat’l. Acad.
`Sci. U.S.A. 84:3891 (1987)
`
`Schroff et al., Human Anti-Murine Immunoglobulin Responses in
`Patients Receiving Monoclonal Antibody Therapy, Cancer Res. 45:879
`(1985)
`
`Abdou et al., Network Theory in Autoimmunity. In vitro suppression of
`serum anti-DNA by anti-idiotypic antibody in systemic lupus
`erythematosus, J. Clin. Invest. 67:1297 (1981)
`
`Harris, L.J. et al. The three-dimensional structure of an intact
`monoclonal antibody for canine lymphoma, Nature 360:369–72 (1992)
`
`Janeway, C.A. et al., IMMUNOBIOLOGY: THE IMMUNE SYSTEM IN
`HEALTH & DISEASE (4th ed., Garland Science Publishing, NY, (1999)
`
`Potter, M. Immunoglobulin-producing tumors and myeloma proteins
`of mice, Physiol. Rev. 52:631–719 (1972)
`
`Kabat K.A. and Wu, T.T. Attempts to locate complementarity-
`determining residues in the variable positions of light and heavy
`chains Ann. NY Acad. Sci. 190:382–93 (1971)
`
`D.R. Davies et al. Antibody-antigen complexes, Ann. Rev. Biochem.
`59:439–73 (1990)
`
`Epp et al., The molecular structure of a dimer composed of the
`variable portions of the Bence Jones protein REI refined at 2.0A
`resolution, Biochem. 14:4943 (1975)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1114
`
`1115
`
`1116
`
`1117
`
`1118
`
`1119
`
`1120
`
`1121
`
`1122
`
`1123
`
`Mian, I.S. Structure, function and properties of antibody binding sites,
`J. Mol. Biol. 217:133–51 (1991)
`
`Poljak et al. The three-dimensional structure of the fab fragment of a
`human myeloma immunoglobulin at 2.0-angstrom resolution, Proc.
`Nat’l Acad. Sci. U.S.A. 71:3440–4 (1974)
`
`Padlan et al. Model building studies of antigen binding sites: The
`hapten binding site ofMOPC315 Cold Spring Harbor Symp. Quant.
`Biol. 41:627–37 (1977))
`
`Boulianne et al. Production of functional chimaeric mouse/human
`antibody, Nature 312:643–6 (1984)
`
`Padlan, E.A. A possible procedure for reducing the immunogenicity of
`antibody variable domains while preserving their ligand-binding
`properties, Mol. Immunol. 28:489–98 (1991)
`
`U.S. Patent No. 6,797,492 Method for Reducing the Immunogenicity of
`Antibody Variable Domains (veneering of CD18 monoclonal
`antibodies) (Filed March 16, 2001)(Issued September 28, 2004)
`
`Padlan, Eduardo A., Choosing The Best Framework To Use In The
`‘Humanization’ Of An Antibody by CDR-Grafting: Suggestions From
`3-D Structural Data. The 2nd Annual IBC International Conference on
`Antibody Engineering. Omni San Diego Hotel, San Diego, CA.
`(December 16–18, 1991)
`
`Suh et al., The galactan-binding immunoglobulin Fab J539: an X-ray
`diffraction study at 2.6-A resolution, Proteins 1:74 (1986)
`
`U.S. Patent No. 5,792,852 Polynucleotides Encoding Modified
`Antibodies with Human Milk Fat Globule Specificity (humanization of
`monoclonal antibodies binding to human milk fat globule antigen)
`(Filed November 16, 1992) (Issued August 11, 1998)
`
`U.S. Patent No. 5,889,157 HumanizedB3 Antibody Fragments, Fusion
`Proteins, and Uses Thereof (humanization of monoclonal antibodies to
`Lewis -related carbohydrate antigen) (Filed October 28, 1994) (Issued
`March 30, 1999)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1124
`
`1125
`
`1126
`
`1127
`
`1128
`
`1129
`
`1130
`
`1131
`
`1132
`
`US Patent No. 5,795,965 Reshaped human antibody to human
`interleukin-6 receptor (claiming priority to April 25, 1991) (Issued
`August 18, 1998)
`
`Furey et al. Structure of a novel Bence-Jones protein (Rhe) fragment at
`1.6 A resolution, J. Mol. Biol. 167:661–92 (1983)
`
`Segal et al. The Three-Dimensional Structure of a Phosphorylcholine-
`Binding Mouse Immunoglobulin Fab and the Nature of the Antigen
`Binding Site, Proc. Nat’l Acad. Sci. U.S.A. 71:4298 (1974)
`
`Jones, TA Diffraction methods for biological macromolecules.
`Interactive computer graphics: FRODO, Meth. Enzymol. 115:157–71
`(1985)
`
`Co, M. et al. Humanized antibodies for antiviral therapy, Proc. Nat’l
`Acad. Sci. U.S.A. 88:2869–73 (1991)
`
`History of Microsoft Excel 1978-2013
`http://www.exceltrick.com/others/history-of-excel/ (accessed August
`29, 2016)
`
`U.S. Patent No. 4,891,762 Method and Apparatus for Tracking,
`Mapping and Recognition of Spatial Patterns (Filed February 9, 1988)
`(Issued January 2, 1990)
`
`Wallick, S. et al. Glycosylation of a VH residue of a monoclonal
`antibody against a(1-6) dextran increases its affinity for antigen, J.
`Exp. Med. 168:1099–109 (1988)
`
`Hale, G. et al. Remission Induction in Non-Hodgkin Lymphoma
`with Reshaped Human Monoclonal Antibody Campath-1H,
`Lancet, Vol. 2, 1394-1399 (1988).
`
`1133
`
`Declaration of Matthew Miner, PH.D.
`
`1134
`
`“Protein Data Bank - Chronology” at
`https://www.nsf.gov/news_summ_jsp?cntn_id=100689 (accessed
`December 28, 2017)
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`SEER Stat Fact Sheets: Breast Cancer, as archived at
`https://web.archive.org/web/20150907161940/http://seer.cancer.gov/st
`atfacts/html/breast.html (accessed December 28, 2017)
`
`History of Microsoft Excel 1978-2013
`http://www.exceltrick.com/others/history-of-excel/ (accessed
`December 28, 2017)
`
`Declaration of Robert V. Cerwinski in Support of Motion for Pro Hac
`Vice Admission
`
`Deposition Transcript of Ian A. Wilson (Apr. 21, 2018)
`
`Deposition Transcript of John Barney Ridgway Brady (Apr. 27, 2018)
`PROTECTIVE ORDER MATERIAL
`
`Deposition Transcript of Paul J. Carter (Apr. 27, 2018)
`PROTECTIVE ORDER MATERIAL
`
`Deposition Transcript of Irene Loeffler (May 1, 2018)
`PROTECTIVE ORDER MATERIAL
`
`Deposition Transcript of Leonard George Presta (May 1, 2018)
`PROTECTIVE ORDER MATERIAL
`
`Second Declaration of Dr. Lutz Riechmann, Ph.D. PROTECTIVE
`ORDER MATERIAL
`
`U.S. Patent 5,821,337
`
`Pauling, The Nature of Chemical Bond and the Structure of Molecules
`and Crystals: An Introduction to Modern Structure Chemistry, Cornell
`University Press (3rd Ed. 1960).
`
`Intentionally Omitted
`
`1135
`
`1136
`
`1137
`
`1138
`
`1139
`
`1140
`
`1141
`
`1142
`
`1143
`
`1144
`
`1145
`
`1146
`to
`1192
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`Foote, Humanized Antibodies, 61 Nova Acta Leopoldine, 269, 103-
`110 (1989) [Carter Deposition Ex. 1193].
`
`Kolbinger et al., Humanization of a Mouse Anti-Human IgE Antibody:
`A Potential Therapeutic for IgE-Mediated Allergies, 6 Protein
`Engineering, 8, 971-980 (1993) [Wilson Deposition Ex. 1194].
`
`David J. King, Applications and Engineering of Monoclonal
`Antibodies (1998) [Wilson Deposition Ex. 1195].
`
`Presta, Humanized Monoclonal Antibodies, 29 Annual Reports in
`Medicinal Chemistry, 32, 317-324 (1994) [Presta Deposition Ex.
`1196].
`
`1193
`
`1194
`
`1195
`
`1196
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on May 25,
`
`2018, I caused copies of the foregoing PETITIONER’S UPDATED EXHIBIT
`
`LIST to be served via email on the following counsel for Patent Owners:
`
`David Cavanaugh (David.Cavanaugh@wilmerhale.com)
`
`Lauren V. Blakely (Laurren.Blakely@wilmerhale.com)
`
`Adam Brausa (abrausa@durietangri.com)
`
`Robert Gunther (Robert.Gunther@wilmerhale.com)
`
`Daralyn Durie (ddurie@durietangri.com)
`
`Lisa Pirozzolo (Lisa.Pirozzolo@wilmerhale.com)
`
`Kevin Prussia (Kevin.Prussia@wilmerhale.com)
`
`
`
`Andrew Danford (Andrew.Danford@wilmerhale.com)
`
`
`/Cynthia Lambert Hardman/
`Cynthia Lambert Hardman
`(Reg. No. 53,179)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`
`
`
`
`
`
`
`
`